Document Detail


Clevidipine Rapidly and Safely Reduces Blood Pressure in Acute Intracerebral Hemorrhage: The ACCELERATE Trial.
MedLine Citation:
PMID:  24135526     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Background: Intracerebral hemorrhage (ICH) causes 10-15% of primary strokes, with mortality related to hematoma volume. Blood pressure (BP) reduction may attenuate hematoma expansion. ACCELERATE (the Evaluation of Patients with Acute Hypertension and Intracerebral Hemorrhage with Intravenous Clevidipine Treatment) is a pilot study representing the first evaluation of safety and efficacy of intravenous clevidipine for the rapid treatment of hypertension in ICH patients. Methods: ICH patients with a systolic BP (SBP) >160 mm Hg who present within 6 h (n = 27) or 12 h (n = 10) of symptoms were prospectively enrolled, treated with open-label clevidipine until SBP ≤160 mm Hg was achieved and then titrated to keep target SBP between 140-160 mm Hg. Results: A total of 35 patients with baseline median Glasgow Coma Scale score of 12, median NIH Stroke Scale score of 14, mean SBP of 186 mm Hg and a mean time from onset of symptoms of 5.5 h received clevidipine. Median time to achieve SBP target range was 5.5 min. All patients achieved target SBP within 30 min; 96.9% achieved target SBP with clevidipine monotherapy. CT scans showed minimal hematoma volume change for the overall population (median change 0.01 ml, -2.9%). Mild/moderate hypotension was reported in 3 patients and resolved with dose reduction or drug discontinuation. Conclusion: Clevidipine monotherapy was effective and safe for rapid BP reduction in this cohort of critically ill ICH patients. Overall, patients showed minimal hematoma expansion with BP reduction, suggesting that rapid BP control with clevidipine may have a beneficial impact on hematoma expansion and warrants further investigation.
Authors:
Carmelo Graffagnino; Sergio Bergese; James Love; Dietmar Schneider; Christos Lazaridis; Marc Lapointe; Kiwon Lee; Gwendolyn Lynch; Ming-Yi Hu; Gregory C Williams
Related Documents :
3571076 - Segmental vascular resistances and compliances in dog lung.
18436696 - Influence of hypercapnic vasodilation on cerebrovascular autoregulation and pial arteri...
24735086 - Chronotropic effect of propofol or alfaxalone following fentanyl administration in heal...
6497446 - Peripheral vasodilatation following 1,1,1-trichloroethane inhalation: peripheral vessel...
10865046 - Effect of ischemia/reperfusion as a systemic phenomenon on anastomotic healing in the l...
2882866 - Baroreceptor function in congestive heart failure: effect on neurohumoral activation an...
Publication Detail:
Type:  Journal Article     Date:  2013-10-12
Journal Detail:
Title:  Cerebrovascular diseases (Basel, Switzerland)     Volume:  36     ISSN:  1421-9786     ISO Abbreviation:  Cerebrovasc. Dis.     Publication Date:  2013  
Date Detail:
Created Date:  2013-10-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100851     Medline TA:  Cerebrovasc Dis     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  173-80     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 S. Karger AG, Basel.
Affiliation:
Duke University Medical Center, Durham, N.C., USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Progression of brain lesions in relation to hyperperfusion from subacute to chronic stages after exp...
Next Document:  Genetic susceptibility for ischemic infarction and arteriolosclerosis based on neuropathologic evalu...